A Machine Learning Model Based on Tumor and Immune Biomarkers to Predict Undetectable MRD and Survival Outcomes in Multiple Myeloma.
Guerrero C, Puig N, Cedena MT, Goicoechea I, Perez C, Garcés JJ, Botta C, Calasanz MJ, Gutierrez NC, Martin-Ramos ML, Oriol A, Rios R, Hernandez MT, Martinez-Martinez R, Bargay J, de Arriba F, Palomera L, Gonzalez-Rodriguez AP, Mosquera-Orgueira A, Gonzalez-Perez MS, Martinez-Lopez J, Lahuerta JJ, Rosiñol L, Blade J, Mateos MV, San-Miguel JF, Paiva B.
Guerrero C, et al.
Clin Cancer Res. 2022 Jun 13;28(12):2598-2609. doi: 10.1158/1078-0432.CCR-21-3430.
Clin Cancer Res. 2022.
PMID: 35063966
Two external validation cohorts were defined by 76 high-risk transplant-eligible patients with smoldering multiple myeloma enrolled in the Grupo Espanol de Mieloma(GEM)-CESAR trial, and 110 transplant-ineligible elderly patients enrolled in the GEM-CLARIDEX trial. ...
Two external validation cohorts were defined by 76 high-risk transplant-eligible patients with smoldering multiple myeloma enrolled in the G …
